Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus paracasei B111H and application thereof to metabolic syndrome

A technology for metabolic syndrome and paracheese, applied in metabolic diseases, medical preparations containing active ingredients, bacteria, etc., can solve the problems of side effects and high price, and achieve the purpose of reducing body weight and blood lipid levels, improving liver steatosis, inhibiting Effects of lipid accumulation in hepatocytes

Active Publication Date: 2021-08-31
BEIJING QUANTIHEALTH TECH CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, statins are considered to be the most effective lipid-lowering drugs at present, and have good effects in clinical treatment, but they need to be taken for a long time, and they are expensive and accompanied by different degrees of side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus paracasei B111H and application thereof to metabolic syndrome
  • Lactobacillus paracasei B111H and application thereof to metabolic syndrome
  • Lactobacillus paracasei B111H and application thereof to metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1. Isolation of strains with hypolipidemic effect

[0045] The feces of several centenarians in the World Longevity Township of Chengmai, Hainan were collected as isolated samples. The collected subjects had never taken antibiotics, probiotics, or gastrointestinal diseases before collection.

[0046] Extract 5 ml of diluent from the collected stool sample, serially dilute 10-fold to 10 -6 , 200 μl of each dilution concentration was spread on selective MRS medium (peptone 10 g, beef extract 10 g, yeast extract 5 g, diammonium hydrogen citrate 2 g, glucose 20 g, Tween 80 1 mL, sodium acetate 5 g, dipotassium hydrogen phosphate 2 g, magnesium sulfate 0.58 g, manganese sulfate 0.25 g, agar 18 g, distilled water 1 000 mL), anaerobic culture at 37°C for 24-48 hours, and different single colonies on the plate were isolated. Pick different single colonies with a sterilized inoculation loop, streak and purify them on a new MRS solid medium plate, culture anaerobically a...

Embodiment 2

[0048] Embodiment 2. Preparation of live bacteria liquid, metabolites and inactivated bacteria

[0049] 2.1 Culture of strains

[0050] Take -80°C frozen bacteria liquid and spread it on the MRS solid plate, and culture it upside down at 37°C for 24-48 hours, then take a single colony and inoculate it in liquid MRS medium, and culture it at 37°C for 18-24 hours to obtain the first-generation bacterial liquid ; Take the first-generation bacterial solution and inoculate it into fresh MRS liquid medium at a concentration of 10%, and incubate at 37°C for 18-24 hours to obtain the second-generation bacterial solution; then take the second-generation bacterial solution and inoculate it into fresh MRS liquid medium at a concentration of 10% In this method, culture at 37°C for 18-24 hours to obtain the working bacterial liquid.

[0051] Obtaining live bacteria

[0052] In a specific embodiment of the present invention, the working bacterial solution obtained in step 1 is placed at 1...

Embodiment 3

[0058] Example 3. Screening and identification of bacterial strains with lipid-lowering effect

[0059] 3.1 Oil red O staining experiment

[0060] The human-derived liver cancer HepG2 cells used in the present invention are purchased from the National Biomedical Experimental Cell Resource Bank, and the culture method is a conventional culture method used in the field. In one embodiment of the invention, the culture method is: At 37°C and 5% CO 2 Cultured in high-glucose DMEM medium containing 10% fetal bovine serum (FBS) under conditions, and added double antibodies (100 μg / ml penicillin and 100 μg / ml streptomycin) in the medium at a ratio of 1:100, every 1 Replace with fresh culture medium once every 2 days, and subculture at a ratio of 1:3-4 after the cells are confluent.

[0061] The bacterial strain provided by the present invention acts on the lipid accumulation model constructed by HepG2 cells, and it is observed that the bacterial strain provided by the present invent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides lactobacillus paracasei B111H and an application thereof to metabolic syndrome, and relates to the technical fields of microorganisms and an application thereof. The lactobacillus paracasei strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No: 22184. The preservation time is April 14, 2021. The lactobacillus paracasei is separated and screened from human excrement, has the effects of remarkably inhibiting liver cell lipid accumulation, reducing body weight and blood fat level and further improving liver fatty degeneration, and has important application significance in relieving hyperlipidemia, obesity and fatty liver. The discovery of the strain provides a new microbial resource for foods or drugs for reducing blood fat.

Description

technical field [0001] The present invention relates to the technical field of microorganisms and applications thereof, in particular to a kind of Lactobacillus paracasei ( Lactobacillus paracasei ) B111H and its application in metabolic syndrome. Background technique [0002] With the improvement of people's living standards, changes in diet structure, accelerated pace of life, and increased pressure, the problem of "three highs" has gradually become serious. The prevalence of dyslipidemia alone is as high as 40.4%. Dyslipidemia is not only an exclusive disease of the elderly, but the patient population is gradually getting younger and has become the "first killer" of young and middle-aged people aged 30 to 50, which has greatly aggravated the severe situation of prevention and control of dyslipidemia-related diseases in my country. Dyslipidemia is an important risk factor for cardiovascular and cerebrovascular diseases. Like many chronic disease risk factors such as hyp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A61K35/747A61P3/06A61P1/16A61P37/02A61P3/04A61P7/00A23L33/135C12R1/225
CPCA61K35/747A23L33/135A61P1/16A61P3/04A61P3/06A61P7/00A61P37/02C12N1/20
Inventor 徐文艺李转羽赵柏闻魏然
Owner BEIJING QUANTIHEALTH TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com